ELND005 in Patients With Mild to Moderate Alzheimer's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).

Key facts

Study ID

NCT00568776

Run by

OPKO Health, Inc.

People needed

353

Starts

2007-12-01

Expected to finish

2010-05-01

Last updated by the study team

2019-11-01

Who can join

Age: 50 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of probable AD
• Age 50 to 85 years, inclusive
• Mini-Mental Status Exam (MMSE) score of 16-26, inclusive
• Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD
• Fluency in English, French, or Spanish
• Stable doses of medications (cholinesterase inhibitors and memantine allowed)
• Caregiver is able to attend all study visits

You may not qualify if…

• Significant neurological disease other than AD
• Major psychiatric disorder
• Significant medical illness
• History of stroke or seizure
• History of a heart attack within the last 2 years
• Prior treatment with certain experimental medicines
• Presence of pacemakers or foreign metal objects in the eyes, skin, or body that would prevent patient from having MRI scan

Where it is running

• Sun Health Research Institute — Sun City, Arizona, United States
• University of Arizona, Health Sciences Center, Dept. of Neurology — Tucson, Arizona, United States
• Margolin Brain Institute — Fresno, California, United States
• Collaborative NeuroScience Network, Inc. — Garden Grove, California, United States
• UCLA Alzheimer's Disease Center, Dept. of Neurology — Los Angeles, California, United States
• UC Irvine Medical Center — Orange, California, United States
• UCSF Medical Center, Dept. of Neurology — San Francisco, California, United States
• Yale University School of Medicine, Alzheimer's Disease Research Unit — New Haven, Connecticut, United States
• Georgetown University Medical Center, Dept. of Neurology — Washington D.C., District of Columbia, United States
• Brain Matters Research, Inc. — Delray Beach, Florida, United States
• Sunrise Clinical Research, Inc — Hollywood, Florida, United States
• Miami Jewish Home and Hospital For The Aged — Miami, Florida, United States
• Avision Research Associates, LLC — Miami, Florida, United States
• Compass Research, LLC — Orlando, Florida, United States
• Roskamp Institute — Sarasota, Florida, United States
• Neurology Clinical Research, Inc. — Sunrise, Florida, United States
• University of South Florida Suncoast Alzheimer's and Gerontology Center — Tampa, Florida, United States
• Premiere Research Institute — West Palm Beach, Florida, United States
• Emory University, Dept. of Neurology — Atlanta, Georgia, United States
• Dekalb Neurology Associates, LLC — Decatur, Georgia, United States
• Department of Neurology - Indiana University Medical Center — Indianapolis, Indiana, United States
• University of Kansas Medical Center, Department of Neurology — Kansas City, Kansas, United States
• Innovative Clinical Concepts — Paducah, Kentucky, United States
• Brigham and Women's Hospital, Dept. of Neurology — Boston, Massachusetts, United States
• Banner Alzheimer's Institute — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.